Our findings affirm that the presence of this mutation in breast cancer patients is associated with distinct clinical presentation: older at diagnosis, higher prevalence of progesterone receptors in the tumor tissue, and, most notably, the patients are more commonly diagnosed with metastatic disease. This evidence concerns the gene PGR and breast carcinoma.